True. Neither is it a foregone conclusion that AVXL will not be approved for all three current indications, including AD. My point is that Rett is very likely, at a minimum, thus the risk-reward at this price is very good. Much better than for a one-trick pony like SAVA.
Market Data 
Markets 
AI
